Topics
Gliomas | Treatment | Targeted therapy | Vorasidenib
Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > Vorasidenib
Lin MD, Tsai AC, Abdullah KG, McBrayer SK, Shi DD.
Treatment
of IDH-mutant glioma in the INDIGO era.
NPJ
Precis Oncol. 2024 Jul 19;8(1):149. doi:
10.1038/s41698-024-00646-2. PMID:
39025958. Review. ˍ
Mullard A.
FDA approves IDH1 and IDH2
inhibitor for brain cancer.
Nat Rev Drug Discov. 2024
Aug 16. doi:
10.1038/d41573-024-00135-y. PMID:
39152244. News˰ ˍ
Nakhate V, Lasica AB, Wen PY.
The Role
of Mutant IDH Inhibitors in the Treatment of Glioma.
Curr
Neurol Neurosci Rep. 2024 Sep 20. doi:
10.1007/s11910-024-01378-3. PMID:
39302605. Review˰ ˍ
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB,
Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz
LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M,
Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G,
Rahman R, Hervey-Jumper S, Chang SM, Wen PY.
The
role of vorasidenib in the treatment of isocitrate
dehydrogenase-mutant glioma.
Neuro
Oncol. 2024 Dec 25:noae259. doi:
10.1093/neuonc/noae259. PMID:
39723472. Review: Interventional study. ˍ